What is Lumoxiti?
Listen to pronunciation. (loo-MOK-sih-tee) A drug used to treat adults with hairy cell leukemia that came back or did not get better with at least two other systemic therapies, including treatment with a purine nucleoside analog (a type of anticancer drug).
Who manufactures Lumoxiti?
AstraZeneca and MedImmune, its global biologics research and development arm, announced today that the US Food and Drug Administration (FDA) has approved Lumoxiti (moxetumomab pasudotox-tdfk) for the treatment of adult patients with relapsed or refractory hairy cell leukaemia (HCL) who have received at least two prior …
How is Lumoxiti administered?
The recommended dose of LUMOXITI is 0.04 mg/kg administered as a 30-minute intravenous infusion on Days 1, 3, and 5 of each 28-day cycle. Continue LUMOXITI treatment for a maximum of 6 cycles, disease progression, or unacceptable toxicity.
Is Lumoxiti an ADC?
There are also two ADCs approved that target CD22: inotuzumab ozogamicin (Besponsa, Pfizer) for relapsed/refractory (R/R) acute lymphoblastic leukaemia and moxetumomab pasudotox (Lumoxiti, AstraZeneca/Innate Pharma) for R/R hairy cell leukaemia.
Is Lumoxiti an antibody-drug conjugate?
With today’s approval of Astrazeneca’s Lumoxiti the US market has two antibody-drug conjugates against the CD22 antigen.
Can you live a long life with hairy cell leukemia?
Hairy cell leukaemia usually develops slowly. It can be kept under control for many years with treatment. Doctors think that most people can expect to have a normal length of life.
Are antibody-drug conjugates considered chemotherapy?
Antibody-drug conjugates or ADCs are a class of biopharmaceutical drugs designed as a targeted therapy for treating cancer. Unlike chemotherapy, ADCs are intended to target and kill tumor cells while sparing healthy cells.
What is payload drug?
The drug payloads are highly active molecules that are too toxic to be administered in their untargeted forms at therapeutic dose levels. This modular approach allows varying targeting ligands, linker systems and drug payloads and generate SMDCs for different diseases.